贝伐珠单抗长期维持治疗晚期非小细胞肺癌39个月的病例报告及相关文献回顾  

Long-term Survival of A Patient with Advanced Non-small Cell Lung Cancer on Bevacizumab Therapy: Case Report and Review of the Literature

作　　者：武玮[1] 唐俊舫[1] 吴羽华[1] 朱允中[1] 徐丽艳[1] 史鹤玲[1] 孟弃逸[1] 刘赞[1] 郭丽丽[1] 陶虹[1] 李明智[1] 刘喆[1] 

机构地区：[1]首都医科大学附属北京胸科医院肿瘤科,北京101149

出　　处：《中国肺癌杂志》2013年第6期325-329,共5页Chinese Journal of Lung Cancer

摘　　要：本文报道1例女性肺腺癌患者,表皮生长因子受体(epidermal growth factor receptor,EGFR)、V-Ki-ras2鼠Kirsten肉瘤病毒致癌基因同源物(V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog,KRAS)基因突变及棘皮动物微管相关类蛋白4与间变性淋巴瘤激酶融合基因(chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase,EML4-ALK)检测结果均为阴性;一线接受贝伐珠单抗(15mg/kg)联合常规剂量紫杉醇、卡铂方案6周期化疗以及后续贝伐珠单抗的维持治疗。共应用贝伐珠单抗42周期,应用总剂量达44,730mg,患者的无进展生存期(progres-sion-free survival,PFS)长达39个月,患者的长期生存获益远超出了不良反应所带来的危害。We report an advanced stage Chinese female lung adenocarcinoma patient who was negative for epidermal growth factor receptor （EGFR）, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog （KRAS） gene mutations, also negative for chinodem microtubule-associated protein-like 4/anaplastic lymphoma kinase （EML4-ALK） gene rearrangement and treated with bevacizumab （15 mg/kg） in combination with 6 cycles of conventional doses of paclitaxel and carboplatin chemotherapy. She was then treated with maintenance bevacizumab for a total of 42 cycles, the total dose of bevacizumab is 44,730 mg. The progression-free survival was 39 months. Our findings suggest that maintenance bevacizumab for the treatment of non-small cell lung cancer （NSCLC） is safe and its benefit for long-term survival overwhelms its side effects.

关 键 词：贝伐珠单抗 化疗 肺肿瘤 

分 类 号：R734.2[医药卫生—肿瘤]